Centauri Therapeutics Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 10
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $2.14M
Latest Deal Amount
  • Investors
  • 5

Centauri Therapeutics General Information

Description

Operator of biotechnology company intended to discover and develop novel molecules targeting life threatening diseases. The company's biotechnology service uses alphamer technology in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections, enabling doctors to treat infectious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Discovery Park
  • Kent CT13 9ND
  • England, United Kingdom
+44 01304 000000

Centauri Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Centauri Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 01-Dec-2018 $2.14M 00.000 000.00 Completed Generating Revenue
3. Accelerator/Incubator 11-Sep-2017 00.000 00.000 Completed Generating Revenue
2. Early Stage VC 20-Feb-2017 $3.13M $6.11M Completed Generating Revenue
1. Early Stage VC 21-Dec-2016 $2.99M $2.99M 000.00 Completed Startup
To view Centauri Therapeutics’s complete valuation and funding history, request access »

Centauri Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 00 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 1,245 $0.003109 $310.73 $310.73 1x $310.73 1.92%
Ordinary 519 $0.003109 $310.58 $310.58 1x $310.58 0.8%
To view Centauri Therapeutics’s complete cap table history, request access »

Centauri Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of biotechnology company intended to discover and develop novel molecules targeting life threatening diseases.
Biotechnology
Kent, United Kingdom
10 As of 2020
00.000
00.00 0000-00-00
0000000000 0 00.000

00000000

on ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit i
0000 000000000
Vienna, Austria
00.000
0000000000 00.000

0000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna a
0000 000000000
Houston, TX
00 As of 0000
000.00
000000000 - 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Centauri Therapeutics Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apeptico Forschung und Entwicklung Venture Capital-Backed Vienna, Austria 00.000 0000000000 00.000
0000000 Venture Capital-Backed Houston, TX 00 000.00 000000000 - 000.00
000000 Venture Capital-Backed Cambridge, United Kingdom 00 00000 0000000000 0 00000
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, United Kingdom 00 00000 000000000 00000
You’re viewing 5 of 14 competitors. Get the full list »

Centauri Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Michael Westby Ph.D Board Member & Chief Executive Officer
Stuart Lawson Board Member & Chief Financial Officer
To view Centauri Therapeutics’s complete executive team members history, request access »

Centauri Therapeutics Board Members (5)

Name Representing Role Since
Clive Dix Ph.D Self Chairman 000 0000
Jonathan Synett NCL Technology Ventures Board Member 000 0000
Michael Westby Ph.D Centauri Therapeutics Board Member & Chief Executive Officer 000 0000
Stuart Lawson Self Board Member & Chief Financial Officer 000 0000
To view Centauri Therapeutics’s complete board members history, request access »

Centauri Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Centauri Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innovate UK Government 000 0000 000000 0
Animatrix Capital Venture Capital Minority 000 0000 000000 0
Discovery Park Other Minority 000 0000 000000 0
NCL Technology Ventures Venture Capital Minority 000 0000 000000 0
Renaissance Capital Partners Growth/Expansion Minority 000 0000 000000 0
To view Centauri Therapeutics’s complete investors history, request access »

Centauri Therapeutics Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 02-Mar-2016 00000 0000000 00000 Drug Discovery 0000000 000000 00.0
Altermune Technologies 18-Jan-2016 Buyout/LBO Therapeutic Devices 0000000 000000 00.0
To view Centauri Therapeutics’s complete investments history, request access »